{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:28:29Z","timestamp":1791509309301,"version":"4.3.4"},"reference-count":33,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"2","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2024,1,10]]},"abstract":"<jats:sec><jats:title>PURPOSE<\/jats:title><jats:p> The addition of checkpoint inhibitors to first-line treatment has prolonged survival of patients with non\u2013small-cell lung cancer (NSCLC), but prognosis remains poor, with new treatment options needed. Canakinumab, a human, monoclonal anti\u2013interleukin (IL)-1\u03b2 antibody, has potential to enhance the activity of PD-L1 inhibitors and chemotherapy (CT) by inhibiting protumor inflammation. <\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p> CANOPY-1 was a phase III, randomized, double-blind study comparing canakinumab (200 mg subcutaneously once every 3 weeks) versus placebo, both combined with pembrolizumab (200 mg intravenously once every 3 weeks) and platinum-based doublet CT, as first-line treatment for advanced\/metastatic NSCLC without EGFR or ALK mutations. The primary end points were progression-free survival (PFS) and overall survival (OS). The secondary endpoints included overall response rate, safety, and patient-reported outcomes. <\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p> Overall, 643 patients were randomly assigned to canakinumab (n = 320) or placebo (n = 323). With a median study follow-up of 6.5 months, the median PFS was 6.8 months with canakinumab versus 6.8 months with placebo (hazard ratio [HR], 0.85; 95% CI, 0.67 to 1.09; P = .102). With a median study follow-up of 21.2 months, the median OS was 20.8 months with canakinumab versus 20.2 months with placebo (HR, 0.87; 95% CI, 0.70 to 1.10; P = .123). No unexpected safety signals were observed for canakinumab combination. Infection rates were comparable between treatment and control arms. A higher frequency of neutropenia and ALT increase (grade \u22642) were reported in the treatment arm. Higher baseline C-reactive protein and IL-6 levels were associated with shorter PFS and OS. Patients treated with canakinumab had clinically meaningful delays in deterioration of lung cancer symptoms, including chest pain and coughing per LC13 and dyspnea per LC13 and C30. <\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p> The addition of canakinumab to first-line pembrolizumab and CT did not prolong PFS or OS in patients with NSCLC. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.23.00980","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T20:55:15Z","timestamp":1701464115000},"page":"192-204","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":94,"title":["Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non\u2013Small-Cell Lung Cancer: Results From the CANOPY-1 Trial"],"prefix":"10.1200","volume":"42","clinical-trial-number":[{"clinical-trial-number":"nct03631199","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6514-6786","authenticated-orcid":false,"given":"Daniel S.W.","family":"Tan","sequence":"first","affiliation":[{"name":"National Cancer Centre Singapore, Duke-NUS Medical School, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7620-0098","authenticated-orcid":false,"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[{"name":"Vall d\u2019Hebron Institute of Oncology, Vall d\u2019Hebron University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8765-3044","authenticated-orcid":false,"given":"Gilberto","family":"de Castro","sequence":"additional","affiliation":[{"name":"Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3059-5730","authenticated-orcid":false,"given":"Benjamin J.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9168-0387","authenticated-orcid":false,"given":"Alastair","family":"Greystoke","sequence":"additional","affiliation":[{"name":"Northern Centre for Cancer Care, Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5562-270X","authenticated-orcid":false,"given":"Byoung Chul","family":"Cho","sequence":"additional","affiliation":[{"name":"Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Cobo","sequence":"additional","affiliation":[{"name":"Medical Oncology Intercenter Unit, Regional University Hospital and Virgen de la Victoria University Hospital, IBIMA, M\u00e1laga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6145-4426","authenticated-orcid":false,"given":"Tae Min","family":"Kim","sequence":"additional","affiliation":[{"name":"Seoul National University Hospital, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8407-6763","authenticated-orcid":false,"given":"Sandip","family":"Ganguly","sequence":"additional","affiliation":[{"name":"Tata Medical Center, Kolkata, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enric","family":"Carcereny","sequence":"additional","affiliation":[{"name":"Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B-ARGO), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1947-3364","authenticated-orcid":false,"given":"Luis","family":"Paz-Ares","sequence":"additional","affiliation":[{"name":"University Hospital 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaafar","family":"Bennouna","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centre Hospitalier Universitaire de Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3821-5598","authenticated-orcid":false,"given":"Marina Chiara","family":"Garassino","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section Hematology Oncology, Thoracic Oncology program, The University of Chicago, Chicago, IL"},{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2645-6391","authenticated-orcid":false,"given":"Michael","family":"Schenker","sequence":"additional","affiliation":[{"name":"Sf Nectarie Oncology Center Craiova and the University of Medicine and Pharmacy of Craiova, Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-We","family":"Kim","sequence":"additional","affiliation":[{"name":"Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1325-2528","authenticated-orcid":false,"given":"Jan C.","family":"Brase","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Bury-Maynard","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8127-3304","authenticated-orcid":false,"given":"Vanessa Q.","family":"Passos","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Deudon","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3628-6990","authenticated-orcid":false,"given":"Bharani","family":"Dharan","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7624-6424","authenticated-orcid":false,"given":"Yuanbo","family":"Song","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5573-0711","authenticated-orcid":false,"given":"Rafael","family":"Caparica","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5252-3677","authenticated-orcid":false,"given":"Bruce E.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"b2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00312-3"},{"key":"b3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy275"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00825"},{"key":"b5","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0025"},{"key":"b6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.1101"},{"key":"b7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03136"},{"key":"b8","first-page":"100001","volume":"1","author":"Garon EB","year":"2020","journal-title":"JTO Clin Res Rep"},{"key":"b9","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2013.45.4.325"},{"key":"b10","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.06.015"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0960"},{"key":"b12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.688625"},{"key":"b13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI80004"},{"key":"b14","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701019"},{"key":"b15","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-017-0022-x"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-2080"},{"key":"b17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1812266115"},{"key":"b18","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.157788"},{"key":"b19","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-22-0290"},{"key":"b20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2015.12.003"},{"key":"b22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32247-X"},{"key":"b23","volume":"80","author":"Johnson BE","year":"2020","journal-title":"Cancer Res"},{"key":"b24","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-CT037"},{"key":"b25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30074-8"},{"key":"b26","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-014-0622-4"},{"key":"b27","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00127-7"},{"key":"b29","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-3176"},{"key":"b30","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016238"},{"key":"b31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082319"},{"key":"b32","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.322"},{"key":"b33","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05874-3"},{"key":"b34","doi-asserted-by":"publisher","DOI":"10.1378\/chest.125.2.439"},{"key":"b35","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-022-01987-x"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.23.00980","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T23:01:02Z","timestamp":1704495662000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.23.00980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,10]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,1,10]]}},"alternative-id":["10.1200\/JCO.23.00980"],"URL":"https:\/\/doi.org\/10.1200\/jco.23.00980","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,10]]},"assertion":[{"value":"2023-05-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-14","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}